Baillie Gifford & Co
RPRX icon

Baillie Gifford & Co’s Royalty Pharma RPRX Stock Holding History

Baillie Gifford & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562M Sell
10,015,578
-6,140,099
-38% -$320M 0.51% 40
2026
Q1 		$775M Sell
16,155,677
-853,091
-5% -$37.4M 0.79% 30
2025
Q4 		$657M Sell
17,008,768
-363,734
-2% -$13.9M 0.55% 38
2025
Q3 		$613M Sell
17,372,502
-647,953
-4% -$23.5M 0.45% 45
2025
Q2 		$649M Buy
18,020,455
+4,618,171
+34% +$153M 0.48% 39
2025
Q1 		$417M Sell
13,402,284
-732,232
-5% -$23.2M 0.36% 53
2024
Q4 		$361M Sell
14,134,516
-1,987,975
-12% -$52.7M 0.28% 68
2024
Q3 		$456M Sell
16,122,491
-230,268
-1% -$6.38M 0.34% 60
2024
Q2 		$431M Sell
16,352,759
-310,033
-2% -$8.59M 0.34% 60
2024
Q1 		$506M Sell
16,662,792
-927,658
-5% -$27.3M 0.39% 54
2023
Q4 		$494M Sell
17,590,450
-650,834
-4% -$17.9M 0.39% 55
2023
Q3 		$495M Sell
18,241,284
-259,304
-1% -$7.7M 0.45% 52
2023
Q2 		$569M Sell
18,500,588
-418,162
-2% -$14.2M 0.48% 50
2023
Q1 		$682M Buy
18,918,750
+1,799,468
+11% +$66.7M 0.62% 40
2022
Q4 		$677M Sell
17,119,282
-748,893
-4% -$31.3M 0.71% 36
2022
Q3 		$718M Sell
17,868,175
-126,743
-0.7% -$5.41M 0.74% 38
2022
Q2 		$757M Buy
17,994,918
+16,867,887
+1,497% +$691M 0.78% 36
2022
Q1 		$43.9M Buy
+1,127,031
New +$44.3M 0.03% 180

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Baillie Gifford & Co's RPRX Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Royalty Pharma (RPRX) stake by 38% in Q2 2026, selling an estimated $320M and leaving 10,015,578 shares worth $562M. The position accounts for 0.51% of the portfolio, ranked #40.

Baillie Gifford & Co first reported a position in RPRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $775M in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Baillie Gifford & Co held 10,015,578 shares of Royalty Pharma worth $562M as of Q2 2026.
  • Baillie Gifford & Co sold 6,140,099 Royalty Pharma shares in Q2 2026, an estimated $320M.
  • Royalty Pharma made up 0.51% of Baillie Gifford & Co's portfolio in Q2 2026, its #40 holding.
  • Baillie Gifford & Co first reported a position in Royalty Pharma in Q1 2022 and has held it in 18 quarters since.
  • Baillie Gifford & Co's Royalty Pharma position peaked at $775M in Q1 2026.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.